111 related articles for article (PubMed ID: 9031471)
1. Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
Vogel GM; van Amsterdam RG; Zandberg P; van Houwelingen P; Kop WJ; van Mensvoort FW; Meuleman DG
Thromb Haemost; 1997 Jan; 77(1):183-9. PubMed ID: 9031471
[TBL] [Abstract][Full Text] [Related]
2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
[TBL] [Abstract][Full Text] [Related]
4. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
5. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost.
Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB
Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836
[TBL] [Abstract][Full Text] [Related]
6. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
[TBL] [Abstract][Full Text] [Related]
9. Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats.
Costantini V; Deveglia R; Stabile A; Nenci GG
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):7-13. PubMed ID: 10691095
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide augments venous and arterial thrombosis in the mouse.
Wang X
Thromb Res; 2008; 123(2):355-60. PubMed ID: 18448153
[TBL] [Abstract][Full Text] [Related]
11. The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis.
Aguejouf O; Oualane FA; Inamo J; Imbault P; Doutremepuich F; Millet J; Theveniaux J; Doutremepuich C
Semin Thromb Hemost; 1996; 22(4):327-33. PubMed ID: 8944417
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of labelled monocytes by experimental venous thrombi.
McGuinness CL; Humphries J; Waltham M; Burnand KG; Collins M; Smith A
Thromb Haemost; 2001 Jun; 85(6):1018-24. PubMed ID: 11434678
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
14. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
[TBL] [Abstract][Full Text] [Related]
15. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Hauptmann J; Barth A; Schönberger FP; Markwardt F
Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
